When.com Web Search

  1. Ad

    related to: xarelto versus eliquis bleeding risk

Search results

  1. Results From The WOW.Com Content Network
  2. Direct factor Xa inhibitors - Wikipedia

    en.wikipedia.org/wiki/Direct_factor_Xa_inhibitors

    The risk of bleeding is increased if used at the same time as other blood thinning drugs such as nonsteroidal anti-inflammatory drugs, antiplatelet drugs and heparin. [2] The blood thinning effects can be reduced if used at the same time as rifampicin and phenytoin , and increased with fluconazole .

  3. Rivaroxaban - Wikipedia

    en.wikipedia.org/wiki/Rivaroxaban

    Rivaroxaban, sold under the brand name Xarelto among others, is an anticoagulant medication (blood thinner) used to treat and prevent blood clots. [8] Specifically it is used to treat deep vein thrombosis and pulmonary emboli and prevent blood clots in atrial fibrillation and following hip or knee surgery. [8]

  4. ELIQUIS® (apixaban) Demonstrates Consistent Reductions in ...

    www.aol.com/news/2012-10-01-eliquis-apixaban...

    ELIQUIS ® (apixaban) Demonstrates Consistent Reductions in Stroke and Systemic Embolism, Major Bleeding and Mortality Compared to Warfarin in Patients with Nonvalvular Atrial Fibrillation at ...

  5. Apixaban - Wikipedia

    en.wikipedia.org/wiki/Apixaban

    Apixaban and other anticoagulants (dabigatran, edoxaban and rivaroxaban) appear equally effective as warfarin in preventing non-hemorrhagic stroke in people with atrial fibrillation and are associated with lower risk of intracranial bleeding. [18] [19]

  6. Factbox-Top Medicare drugs headed for price cuts - AOL

    www.aol.com/news/factbox-top-medicare-drugs...

    Eliquis rival Xarelto from Johnson & Johnson cost Medicare more than $6 billion between June 2022 and May 2023. The bloodthinner, which was used to treat 1.3 million enrollees, can lower the risk ...

  7. U.S. FDA Approves ELIQUIS® (apixaban) to Reduce the Risk of ...

    www.aol.com/news/2013-01-02-us-fda-approves...

    U.S. FDA Approves ELIQUIS ® (apixaban) to Reduce the Risk of Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation ELIQUIS Demonstrated Superior Risk Reductions Versus ...

  8. ELIQUIS® (apixaban) Demonstrated Superiority In Reducing A ...

    www.aol.com/news/2012-12-08-eliquis-apixaban...

    Rates of composite major bleeding or clinically relevant non-major bleeding were 2.7% in the placebo group, 3.2% in the ELIQUIS 2.5 mg group, and 4.3% in the ELIQUIS 5 mg group.

  9. Warfarin necrosis - Wikipedia

    en.wikipedia.org/wiki/Warfarin_necrosis

    Warfarin-induced skin necrosis is a condition in which skin and subcutaneous tissue necrosis (tissue death) occurs due to acquired protein C deficiency following treatment with anti-vitamin K anticoagulants (4-hydroxycoumarins, such as warfarin).